The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A Phase Ib, Open-Label, Multi-Center Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of AZD1775 Monotherapy in Patients with Advanced Solid Tumors: Expansion Cohorts.
 
Todd Michael Bauer
No Relationships to Disclose
 
Suzanne Fields Jones
No Relationships to Disclose
 
Carol Greenlees
No Relationships to Disclose
 
Carl Cook
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Philip John Jewsbury
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Ganesh Mugundu
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Tim French
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Andrew J Pierce
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Mark J. O'Connor
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Naomi Laing
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
J Carl Barrett
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Dawn Michelle Stults
No Relationships to Disclose
 
Melissa Lynne Johnson
Honoraria - Genentech
Consulting or Advisory Role - Astellas Pharma (I); Otsuka (I)
Research Funding - Novartis
 
J. Thaddeus Beck
Consulting or Advisory Role - Novartis
Research Funding - AbbVie (Inst); Amgen (Inst); AstraZeneca (Inst); Genentech/Roche (Inst); Heat Biologics (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst)
 
Kathleen N. Moore
Consulting or Advisory Role - Advaxis; Amgen (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst); Immunogen (Inst); Merrimack
 
Jeffrey R. Infante
No Relationships to Disclose
 
Howard A. Burris
No Relationships to Disclose
 
David R. Spigel
Stock and Other Ownership Interests - Foundation Medicine; Illumina
Consulting or Advisory Role - AstraZeneca; Biodesix; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech/Roche; Lilly; Novartis; Pfizer
Speakers' Bureau - Novartis
Research Funding - Amgen (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); BIND Biosciences (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); CytRx Corporation (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Genentech/Roche (Inst); ImClone Systems (Inst); Immunogen (Inst); Lilly (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); Peregrine Pharmaceuticals (Inst); Pfizer (Inst); University of Texas Southwestern Medical Center - Simmons Cancer Center (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Biodesix; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech/Roche; Lilly; Novartis; Pfizer